Buzzeo B D, Heisey D M, Messing E M
University of Wisconsin School of Medicine, Madison, USA.
Urology. 1997 Oct;50(4):525-8. doi: 10.1016/S0090-4295(97)00305-1.
To determine if there is an increased rate of occurrence of bladder cancer in renal transplant recipients.
We reviewed the records of 3130 consecutive renal transplant recipients at the University of Wisconsin Hospital from 1980 to 1994. We then compared the rate of occurrence of bladder cancer in this population with that of the general population of Wisconsin. Using an age-specific hazard model based on the rate of bladder cancer in the general population of Wisconsin, we predicted the expected number of bladder cancer cases in this renal transplant population.
Using this model, one would expect 1.81 cases of bladder cancer in the renal transplant data set, as opposed to the observed 6, resulting in a relative risk of 3.31 of developing bladder cancer as a result of renal transplantation.
There is a higher incidence of bladder cancer in renal transplant recipients. Therefore, despite a higher incidence of hematuria in this population, each noninfected patient with microscopic (or gross) hematuria should undergo a careful urologic evaluation.
确定肾移植受者膀胱癌的发生率是否增加。
我们回顾了1980年至1994年在威斯康星大学医院连续接受肾移植的3130名受者的记录。然后我们将该人群中膀胱癌的发生率与威斯康星州普通人群的发生率进行了比较。使用基于威斯康星州普通人群膀胱癌发生率的年龄特异性风险模型,我们预测了该肾移植人群中膀胱癌病例的预期数量。
使用该模型,在肾移植数据集中预计有1.81例膀胱癌病例,而观察到的为6例,导致肾移植后患膀胱癌的相对风险为3.31。
肾移植受者中膀胱癌的发病率较高。因此,尽管该人群血尿发病率较高,但每位未感染的镜下(或肉眼)血尿患者均应接受仔细全面的泌尿外科评估。